Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Mirum Pharmaceuticals Inc. manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct examiners and 4 distinct art units. The busiest examiner, SCHMIDT, IZABELA MARIA, is responsible for 1 pending office action, indicating that the workload is not concentrated under a single individual.
The presence of 4 distinct art units for 5 pending office actions suggests that the company's pharmaceutical research is being evaluated across several specialized groups within the USPTO. This requires a prosecution strategy that accounts for the specific guidelines of 4 distinct art units. With 5 distinct examiners involved, the applicant must manage five different sets of examiner preferences and backgrounds.
Because the busiest examiner, SCHMIDT, IZABELA MARIA, has only 1 pending action, the portfolio's activity is evenly spread across the identified examiners. This distribution means that the success of the portfolio is not dependent on a single examiner but is instead subject to the varied interpretations of 5 distinct individuals. Practitioners should coordinate responses to ensure consistency across the 4 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.3% | +42.5% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
| MCANANY, JOHN D | 1 | 67.2% | +43.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18382636 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | SCHMIDT, IZABELA MARIA | — |
| 17981033 | TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS) | SZNAIDMAN, MARCOS L | — |
| 17972909 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | GALSTER, SAMUEL LEONARD | — |
| 17973194 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | SHOWALTER, ALEXANDER KEITH | — |
| 17430210 | METHODS FOR TREATING CHOLESTASIS | MCANANY, JOHN D | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1628 | 1 |
| 1693 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18382636 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | SCHMIDT, IZABELA MARIA | 1629 | §102§103DP | Non-Final OA | — | Pending | Oct 23, 2023 |
| 17981033 | TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS) | SZNAIDMAN, MARCOS L | 1628 | §103DP | Final Rejection | — | Pending | Nov 04, 2022 |
| 17972909 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | — | Pending | Oct 25, 2022 |
| 17973194 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | SHOWALTER, ALEXANDER KEITH | 1629 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2022 |
| 17430210 | METHODS FOR TREATING CHOLESTASIS | MCANANY, JOHN D | 1625 | §103DP | Final Rejection | — | Pending | Aug 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial